Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes - PubMed (original) (raw)

Clinical Trial

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes

Antonio Ceriello et al. Diabetes Care. 2005 Feb.

Erratum in

Diabetes Care. 2005 May;28(5):1272

Abstract

Objective: Pioglitazone, metformin, and gliclazide lower HbA(1c) and fasting plasma glucose in patients with type 2 diabetes. We compared the effects of these three drugs, used as monotherapy and in combination, on postload glycemia and composite insulin sensitivity index (CISI) in these patients.

Research design and methods: Postload glycemia and CISI were analyzed for 940 patients who had oral glucose tolerance tests (OGTTs) in four multicenter, randomized, double-blind, double-dummy, parallel group clinical trials (pioglitazone versus metformin, pioglitazone versus gliclazide, pioglitazone plus sulfonylurea versus metformin plus sulfonylurea, and pioglitazone plus metformin versus gliclazide plus metformin). Plasma glucose and insulin were determined during the 3-h OGTT performed at baseline and after 1 year of therapy. Incremental area under the curve for glucose was the surrogate for postload glycemia. CISI was calculated using the formula {10,000/ radical of [(fasting glucose x fasting insulin) x (mean glucose x mean insulin)]} during the OGTT.

Results: In monotherapy, pioglitazone reduced postload glycemia and enhanced CISI more than metformin and gliclazide. In combination therapy, pioglitazone plus sulfonylurea reduced postload glycemia and increased CISI more than metformin plus sulfonylurea. Pioglitazone plus metformin also decreased postload glycemia and increased CISI more than gliclazide plus metformin.

Conclusions: Pioglitazone improves postload glycemia and CISI more than metformin or gliclazide when used as monotherapy or in combination therapy in patients with type 2 diabetes.

PubMed Disclaimer

Cited by

Efficacy of berberine in patients with type 2 diabetes mellitus.
Yin J, Xing H, Ye J. Yin J, et al. Metabolism. 2008 May;57(5):712-7. doi: 10.1016/j.metabol.2008.01.013. Metabolism. 2008. PMID: 18442638 Free PMC article. Clinical Trial.
Polymorphisms of the KCNQ1 gene are associated with the therapeutic responses of sulfonylureas in Chinese patients with type 2 diabetes.
Li Q, Tang TT, Jiang F, Zhang R, Chen M, Yin J, Bao YQ, Cheng X, Hu C, Jia WP. Li Q, et al. Acta Pharmacol Sin. 2017 Jan;38(1):80-89. doi: 10.1038/aps.2016.103. Epub 2016 Oct 3. Acta Pharmacol Sin. 2017. PMID: 27694910 Free PMC article. Clinical Trial.
Comparative Study on Adding Pioglitazone or Sitagliptin to Patients with Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin.
Jameshorani M, Sayari S, Kiahashemi N, Motamed N. Jameshorani M, et al. Open Access Maced J Med Sci. 2017 Dec 12;5(7):955-962. doi: 10.3889/oamjms.2017.193. eCollection 2017 Dec 15. Open Access Maced J Med Sci. 2017. PMID: 29362626 Free PMC article.
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.
Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Salpeter SR, et al. Cochrane Database Syst Rev. 2010 Apr 14;2010(4):CD002967. doi: 10.1002/14651858.CD002967.pub4. Cochrane Database Syst Rev. 2010. PMID: 20393934 Free PMC article. Review.

Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes - PubMed (original) (raw)